A major new review paper titled, High-dose vitamin C: A promising anti-tumor agent, insight from mechanisms, clinical research, and challenges, analyzed 150+ studies and found that when vitamin C reaches true pharmacologic levels (20–30 mM), it behaves like a targeted, tumor-selective therapy — something past trials missed by under-dosing. The evidence base spans decades of laboratory, animal, and early-phase clinical research.

The authors outline four major anti-cancer mechanisms of high-dose vitamin C — pro-oxidative tumor cytotoxicity, epigenetic reprogramming, suppression of oncogenic signaling pathways, and powerful immune activation.

.

.

For a therapy this safe, inexpensive, and mechanistically potent, the findings are striking. Here’s what they found:

When plasma levels reach the 20–30 mM range, vitamin C switches from antioxidant to pro-oxidant, generating hydrogen peroxide and hydroxyl radicals inside tumors — while sparing normal tissues.

Tumors are uniquely vulnerable because they accumulate:

• excess labile iron
• high GLUT1 expression (massive vitamin C uptake)
• weakened redox defenses

This combination creates a selective chemical trap that cancer cells cannot escape.

The review highlights a major vulnerability: KRAS- and BRAF-driven colorectal, pancreatic, and lung cancers are selectively disrupted — even destroyed — by pharmacologic vitamin C.

These mutations cause:

• extreme GLUT1 overexpression
• glycolytic addiction (the “Warburg effect”)
• rapid NADPH and glutathione depletion

This makes the cancer cells especially sensitive to vitamin C–induced metabolic collapse.

A Phase III clinical trial even reported significantly improved survival in KRAS-mutant colorectal cancer patients when high-dose intravenous vitamin C was added to standard therapy.

Vitamin C is a required cofactor for the enzymes that degrade HIF-1α, a central regulator of tumor aggressiveness. At pharmacologic doses, high-dose intravenous vitamin C shuts down:

• angiogenesis
• metastatic signaling
• hypoxia tolerance
• GLUT1 upregulation

Very few agents directly dismantle this survival pathway.

Pharmacologic vitamin C reactivates TET enzymes, reversing abnormal DNA hypermethylation and restoring tumor-suppressor gene expression.

Multiple studies show induced differentiation and suppressed proliferation following high-dose intravenous vitamin C exposure.

High-dose intravenous vitamin C also strengthens the immune system’s ability to attack cancer. It has been shown to:

• Increase CD4⁺ and CD8⁺ T-cell infiltration into tumors
• Boost granzyme B and IL-12, enhancing cytotoxic activity
• Upregulate CXCL9/10/11, drawing more tumor-infiltrating lymphocytes
• Synergize with PD-1 and CTLA-4 checkpoint inhibitors
• Enhance T-cell function and proliferation
• Improve natural killer (NK) cell cytotoxicity
• Activate dendritic cells, strengthening antigen presentation

Together, these actions amplify immune-mediated tumor destruction.

The review summarizes multiple Phase I/II trials where high-dose intravenous vitamin C strengthened standard therapy:

• Pancreatic cancer: major tumor shrinkage in 8/9 patients
• Glioblastoma: median overall survival increased from 14.6 → 19.6 months
• NSCLC: response rates roughly doubled
• Ovarian cancer: reduced chemotherapy toxicity + longer progression-free survival

Across all studies, safety and tolerability were excellent.

The review identifies the dosing regimen required to achieve tumor-selective, cytotoxic plasma levels:

75–100 grams IV per infusion, or >1.0 g/kg IV per infusion

Given 2–3 times per week for 6–8 cycles.

This reliably produces ≥20 mM plasma concentrations — the range associated with selective cancer cell killing — while remaining well-tolerated.

The authors also emphasize that most patients in clinical trials never reached the maximum tolerated dose, suggesting the therapeutic ceiling is likely far higher than what past studies explored.

*

This paper makes something very clear: Pharmacologic intravenous vitamin C is a multi-mechanistic, tumor-selective anti-cancer therapy that has been under-dosed, under-studied, and consistently underestimated.

Given its safety profile, low cost, and robust mechanistic data, high-dose vitamin C urgently warrants modern Phase III trials with appropriate pharmacologic dosing regimens.

*

Click the share button below to email/forward this article. Follow us on Instagram and X and subscribe to our Telegram Channel. Feel free to repost Global Research articles with proper attribution.

Nicolas Hulscher, MPH, Epidemiologist and Foundation Administrator, McCullough Foundation

Featured image copyright Tobias Arhelger – Fotolia

Global Research is a reader-funded media. We do not accept any funding from corporations or governments. Help us stay afloat. Click the image below to make a one-time or recurring donation.